Pfizer will appeal court decision regarding celebrex reissue patent

17-03-2014 Business Wire HealthComments (0)

BiotechnologyCelebrexPfizerUSA

Pfizer confirmed today that the United States District Court for the Eastern District of Virginia granted summary judgment invalidating the reissue patent (US Patent No RE44,048), covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex. Pfizer disagrees with the ruling and will pursue all available remedies, including an immediate appeal of the court’s decision. A trial was scheduled to begin

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top